Skip to main content

Usman Nassim's Form 4 filing

Gyre Therapeutics, Inc. (GYRE) · filed May 2, 2024

Accession no.
0001140361-24-024125
Filed
May 2, 2024
Trade date
May 1, 2024
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $282.6K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Usman NassimCIK 0001206872Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 1, 2024Common StockMOption exerciseAcquired+20,000$6.93+$138,60021,636Direct
May 1, 2024Common StockSSaleDisposed−14,900$13.86−$206,5146,736Direct
May 1, 2024Common StockSSaleDisposed−5,000$14.90−$74,5001,736Direct
May 1, 2024Common StockSSaleDisposed−100$15.63−$1,5631,636Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 1, 2024Common StockMOption exerciseDisposed−20,000$0.00$0281,652Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)